期刊文献+

外周血胰岛素样生长因子Ⅱ-mRNA对肝癌的诊断价值 被引量:1

Amplification of Peripheral Blood Insulin-like Growth Factor Ⅱ-mRNA and its Clinical Significance in Diagnosis and Prognosis of Hepatocellular Carcinoma
原文传递
导出
摘要 目的探讨外周血胰岛素样生长因子Ⅱ(IGF-II)-mRNA在肝癌诊断和判断预后中的价值。方法从癌组织和外周血中制备总RNA,经随机引物和逆转录酶作用合成IGF-ⅡcDNA,再分别以RT-PCR扩增IGF-ⅡcDNA片段,分析其在肝病诊断与鉴别中的临床价值。结果肝癌组织和外周血中扩增出的IGF-Ⅱ基因片段大小为170bp,并与原设计相一致。肝癌、癌灶周围和远癌组织中,IGF-Ⅱ基因检出率分别为100%、53.3%和0。肝癌患者外周血IGF-II基因片段阳性率34.2%,在Ⅰ、Ⅱ和Ⅲ期肝癌中分别为14.3%、19.4%和45.5%,在伴有肝外转移肝癌中全数阳性,在AFP<50ng/ml的17例中阳性6例(35.3%);肝硬化、慢性肝炎、急性肝炎和肝外肿瘤组中未见IGF-Ⅱ基因片段阳性。IGF-Ⅱ基因标志与肝癌大小间差异无统计学意义(P>0.05)。结论外周血IGF-Ⅱ基因分析有助于肝癌的诊断、转移判别及术后复发的监测。 Objective To explore clinical values of peripheral blood insulin-like growth factor Ⅱ (IGF-Ⅱ )genes markers in diagnosis and differential diagnosis of hepatocellular careinoma(HCC). Meth- otis Total RNAs were extracted from human hepatoma tissues and peripheral blood and synthesized to IGF-Ⅱ cDNA through random primers and reverse transcriptase,amplified by a nested polymerase chain reaction assay,and the clinical values of IGF-Ⅱ gene marker were analyzed in patients with liver dis- eases. Results The fragments of IGF-Ⅱ mRNA amplified by RT-PCR were identical to the original designed ones with size of 170bp. The fragments of IGF-Ⅱ mRNA were seen with 100% in cancerous, 53.5% in paracancerous and 0 in distal cancerous tissues, respectively. The incidence of peripheral blood IGF-Ⅱ gene fragments was 34.2% in HCC, 0 in liver cirrhosis, chronic hepatitis, acute hepatitis, and extrahepatic tumor, respectively. The presence of IGF- Ⅱ mRNA correlated with the stage of HCC and the persence of intrahepatic metastasis. The IGF- Ⅱ mRNA was found in all metastasis at extrahep- atic organs (100%), The positive rate of IGF-Ⅱ was 35.5% in HCC patients with AFP〈50ng/ml. No sig- nificant correlation was found between tumer size and IGF-Ⅱ gene expression. Conclusion The pre- sent data suggest that the gene analysis of peripheral blood IGF-Ⅱ is useful for HCC diagnosis ,differ- entiation of extrahepatic metastasis and monitoring postoperative recurrence..
出处 《苏州大学学报(医学版)》 CAS 北大核心 2009年第4期684-687,共4页 Suzhou University Journal of Medical Science
基金 江苏省医学重点人才基金资助项目(RC2003100)
关键词 肝癌 胰岛素样生长因子Ⅱ 基因扩增 诊断 hepatocellular carcinoma IGF-Ⅱ gene amplification diagnosis
  • 相关文献

参考文献8

  • 1Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocelular carcinoma[J]. Nat Genet, 2002,31 (4): 339-346.
  • 2Lee YI, Lee S, Das GC, et al. Activation of the insulin- like growth factor Ⅱ transcription complexes;implications for a gain-If-function during the formation of hepatocelular carcinoma[J], Oncogene, 2000:19(33):3717-3726.
  • 3Tetesuro S, Kankastsu Y, Kaoru S, et al. Increased expression of insulin-like growth factor Ⅱ in hepatocellular carcinoma is primarily regulated at the transcriptional level[J]. Lab Invest,1996,75(2):307-311.
  • 4中华医学会传染病与,寄生虫病学分会,肝病学分会.病毒性肝炎防治方案[J].中华肝脏病杂志,2000,8(6):324-329. 被引量:14010
  • 5Seo JH, Park BC. Expression of insulin-like growth factor Ⅱ in chronic hepatitis B,liver cirrhosis,and hapatocellullar carcinoma[J]. Gan kagaku Ryoho,1995,22(3):292-307.
  • 6Scharf JG, Braulke T. The role of the IGF axis in hepatocarcinogenesis [J].Horm Metab Res,2003,35 ( 11-12):685- 693.
  • 7Lee YM, Bae MH, Lee OH, et al. Synergistic induction of in vivo angiogenesis by the combination of insulin-like growth factor-Ⅱ and epidermal growth factor [J].Oncol Rep,2004,12 ( 4 ) :843 -848.
  • 8Yao DF, Jiang DR, Huang ZW, et al. abnormal expression of hepatoma specific r-glutamyl transferase and alteration of r-glutamyl transferase gene methylation status in patients with hepatocellular carcinoma [J].Cancer,2000,88(4): 761-769.

共引文献14009

同被引文献13

  • 1Kladney RD,Bulla GA, Guo L, et al. GP-73, a novelGolgi localized protein upregulated by viral infection [ J]Gene,2000,249(1 -2) :53 -65.
  • 2Block TM,Comunale MA,Lowman M,et al. Use of tar-geted glycoproteomics to identify serum glycoproteins thatcorrelate with liver cancer in woodchucks and humans[ J]Proc Natl A cad Sci USA,2005,102(3) :779 -784.
  • 3Marrero J A, Romano PR, Nikolaeva 0,et al. GP73 , aresident Golgi glycoprotein, is a novel serum marker forhepatocellular carcinoma [ J] J Hepatol,2005,43 ( 6 ):1007 -1012.
  • 4Rabouille C, Jokitalo E. Golgiapparatus partitioning duringcell division[ J] Momemb Biol,2003 ,20(2) :117 - 127.
  • 5Park JY, Ikeda H, Ikenaga T, et al. Acetylcholine recep-tors enable the transport of rapsyn from the Golgi complexto the plasma membrane [J] , J Neurosci ,2012,32(21 ):7356 -7363.
  • 6Mukherjee S, Chiu R, Leung SM, et al. Fragmentation ofthe Golgi apparatus : an early apoptotic event indepent ofthe cytoskeleton[ J] Traffic,2007 ,8(4) :369 -378.
  • 7Ohashi Y, Iijima H, Yamaotsu N,et al. AMF-26, a no-vel inhibitor of the Golgi system, targeting ADP-ribosyla-tion factor 1 ( Arfl ) with potential for cancer therapy [ J]J Biol Chem,2012,287(6) :3885 -3897.
  • 8Iftikhar R,Kladney RD,Havlioglu N,et al. Disease andcell specific expression of GP73 in human liver disease[J] Am J Gastro-enterol,2004,99(6) : 1087 - 1095.
  • 9Norton P A, Comunale MA, Krakover J, et al. N-linkedglycosylation of the liver cancer biomarker GP73 [ J] JCell Biochem,2008,104( 1) :136 - 149.
  • 10Haybaeck J, Zeller N, Wolf M J, ei al. A lymphotoxin-driv-en pathway to hepatocellular carcinoma [ J] CancerCell,2009,16(4) :295 -308.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部